Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(1):61-67; doi:10.1093/jnci/94.1.61
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Geisler, J. P.
Right arrow Articles by Buller, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Geisler, J. P.
Right arrow Articles by Buller, R. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 1, 61-67, January 2, 2002
© 2002 Oxford University Press

ARTICLE

Frequency of BRCA1 Dysfunction in Ovarian Cancer

John P. Geisler, Melanie A. Hatterman-Zogg, Jennifer A. Rathe, Richard E. Buller

Affiliation of authors: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Holden Comprehensive Cancer Center, University of Iowa, Iowa City.

Correspondence to: Richard E. Buller, M.D., Ph.D., Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, 200 Hawkins Dr., Iowa City, IA 52242 (e-mail: richard-buller{at}uiowa.edu).

Background: Ovarian cancer is one of the most common hereditary cancers in women. Mutations in the BRCA1 gene increase a woman's risk of ovarian cancer. Testing for BRCA1 mutations is cumbersome and impractical for large populations. Therefore, we developed an efficient strategy to detect various types of BRCA1 dysfunction and also determined the relative frequency of BRCA1 dysfunction in ovarian cancer. Methods: Tumors from 221 patients with epithelial ovarian cancer were screened for loss of heterozygosity (LOH) at the BRCA1 locus. BRCA1 complementary DNA (cDNA) and genomic DNA from all cancers with BRCA1 LOH (106 tumors) or noninformative status (15 tumors) were polymerase chain reaction (PCR) amplified and analyzed for protein truncation in a coupled transcription/translation test. When truncated BRCA1 protein was detected, the BRCA1 gene from both the tumor and a paired blood sample was sequenced. When BRCA1 expression in tumor cDNA was not detected with a protein truncation test, a methylation-specific PCR was used to determine whether the promoter region of BRCA1 was methylated and thus inactivated. All statistical tests were two-sided. Results: Fifty-one (23.1%) of 221 tumors had BRCA1 dysfunction, including 18 with germline mutations, 15 with somatic mutations, and 18 with monoallelic or biallelic hypermethylated promoters. By the consideration of only tumors with LOH or that were noninformative, the efficiency for detecting BRCA1 dysfunction improved to 45 (37.2%) of 121 tumors. Therefore, LOH/noninformative was a strong predictor of mutation status (Fisher's exact test, P<.001). However, this subset of tumors did not include those with BRCA1 missense mutations (estimated at six [2.7%] of 221 not detected by our method) or biallelic promoter methylation (estimated at six [2.7%] of 221). Conclusions: BRCA1 dysfunction in ovarian cancer is common and occurs via multiple mechanisms. The use of LOH, rather than a family history of ovarian cancer, as a first step in a screening strategy, followed by protein truncation testing, appears to increase the chance of identifying tumors with BRCA1 dysfunction.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Mol. Diagn.Home page
A. Melnikov, D. Scholtens, A. Godwin, and V. Levenson
Differential Methylation Profile of Ovarian Cancer in Tissues and Plasma
J. Mol. Diagn., January 1, 2009; 11(1): 60 - 65.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. S.P. Tan, C. Rothermundt, K. Thomas, E. Bancroft, R. Eeles, S. Shanley, A. Ardern-Jones, A. Norman, S. B. Kaye, and M. E. Gore
"BRCAness" Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated With BRCA1 and BRCA2 Mutations
J. Clin. Oncol., December 1, 2008; 26(34): 5530 - 5536.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. D. Kauff
Is It Time to Stratify for BRCA Mutation Status in Therapeutic Trials in Ovarian Cancer?
J. Clin. Oncol., January 1, 2008; 26(1): 9 - 10.
[Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
W W J de Leng, J J Keller, S Luiten, A R Musler, M Jansen, A F Baas, F W M de Rooij, J J P Gille, F H Menko, G J A Offerhaus, et al.
STRAD in Peutz-Jeghers syndrome and sporadic cancers
J. Clin. Pathol., October 1, 2005; 58(10): 1091 - 1095.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. L. Hilton, J. P. Geisler, J. A. Rathe, M. A. Hattermann-Zogg, B. DeYoung, and R. E. Buller
Inactivation of BRCA1 and BRCA2 in Ovarian Cancer
J Natl Cancer Inst, September 18, 2002; 94(18): 1396 - 1406.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. E. Buller, M. S. Shahin, J. P. Geisler, M. Zogg, B. R. De Young, and C. S. Davis
Failure of BRCA1 Dysfunction to Alter Ovarian Cancer Survival
Clin. Cancer Res., May 1, 2002; 8(5): 1196 - 1202.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.